1)Al-Aly Z, Xie Y, Bowe B: High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594: 259-264, 2021
2)Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, et al: Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 18: e1003773, 2021[doi: 10.1371/journal.pmed.1003773]
3)Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ: 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8: 416-427, 2021
4)Mehandru S, Merad M: Pathological sequelae of long-haul COVID. Nat Immunol 23: 194-202, 2022
5)新型コロナウイルス感染症診療の手引き別冊 罹患後症状のマネジメント編集委員会: 新型コロナウイルス感染症診療の手引き別冊 罹患後症状のマネジメント 第1.1版. 2022 https://www.mhlw.go.jp/content/000952747.pdf(最終閲覧日: 2022年6月21日)
6)A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1(最終閲覧日: 2022年4月13日)
7)日本鼻科学会嗅覚障害診療ガイドライン作成委員会: 嗅覚障害診療ガイドライン. 日鼻誌56: 487-556, 2017
8)Duncan A, Yacoubian C, Watson N, Morrison I: The risk of copper deficiency in patients prescribed zinc supplements. J Clin Pathol 68: 723-725, 2015
9)Rowin J, Lewis SL: Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation. J Neurol Neurosurg Psychiatry 76: 750-751, 2005
10)河月 稔: 第1章 嗅覚検査. 医学検査66: 84-89, 2017
11)Griffanti L, Raman B, Alfaro-Almagro F, Filippini N, Cassar MP, et al: Adapting the UK biobank brain imaging protocol and analysis pipeline for the C-MORE multi-organ study of COVID-19 survivors. Front Neurol 12: 753284, 2021[doi: 10.3389/fneur.2021.753284]
12)Gruenstein D, O'Mara M, Pa SH, Levitt J, Pa SL, et al: Telogen effluvium caused by COVID-19 in Elmhurst, New York: report of a cohort and review. Dermatol Online J 27, 2021[doi: 10.5070/D3271055619]
13)Nguyen B, Tosti A: Alopecia in patients with COVID-19: a systematic review and meta-analysis. JAAD Int 7: 67-77, 2022
14)Chadda KR, Blakey EE, Huang CL, Jeevaratnam K: Long COVID-19 and postural orthostatic tachycardia syndrome- is dysautonomia to be blamed? Front Cardiovasc Med 9: 860198, 2022[doi: 10.3389/fcvm.2022.860198]
15)Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, et al: SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 2022[doi: 10.1038/s41586-022-04569-5]
16)髙尾昌樹: COVID-19における神経病理の重要性と課題. Brain Nerve 72: 1061-1065, 2020
17)髙尾昌樹: COVID-19による中枢神経系への影響. 臨精薬理24: 989-994, 2021
18)髙尾昌樹: COVID-19の神経障害 髄膜脳炎・脳症. Clin Neurosci 39: 335-337, 2021
19)髙尾昌樹, 水澤英洋, 中嶋秀人: COVID-19の神経障害 わが国の現状—NCNPと日本神経学会による調査結果. Clin Neurosci 39: 319-322, 2021
20)Mizutani M, Nakayama Y, Saitoh Y, Ariga H, Enokida T, et al: Pathologic and neuropathologic study of a case of COVID-19. JMAJ 5: 157-160, 2022
21)Rutkai I, Mayer MG, Hellmers LM, Ning B, Huang Z, et al: Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat Commun 13: 1745, 2022[doi: 10.1038/s41467-022-29440-z]